Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Sylvain Ladoire; Jean-Christophe Eymard; Sylvie Zanetta; Grégoire Mignot; Etienne Martin; Isabelle Kermarrec; Eric Mourey; Frédéric Michel; Luc Cormier; François Ghiringhelli

Journal articles

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Sylvain Ladoire ^{1, 2, *} Jean-Christophe Eymard ³ Sylvie Zanetta ¹ Grégoire Mignot ² Etienne Martin ⁴ Isabelle Kermarrec ⁵ Eric Mourey ⁵ Frédéric Michel ⁵ Luc Cormier ⁵ François Ghiringhelli ^{1, 2}

* Corresponding author

1 Département d'oncologie médicale [Centre Georges-François Leclerc]

2 LNC - Lipides - Nutrition - Cancer (U866)

3 Service d'oncologie médicale

4 Service de radiothérapie [Centre Georges-François Leclerc]

5 Service d'urologie

Abstract : For this patient population, low dose metronomic cyclophosphamide prednisolone might be a viable alternative. Its convenient oral administration, low cost, and lack of toxicity justify further studies alone, or in combination with other agents in HRPC patients.

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Immunology

Complete list of metadatas

https://www.hal.inserm.fr/inserm-00555027
Contributor : Grégoire Mignot <>
Submitted on : Wednesday, January 12, 2011 - 9:17:19 AM
Last modification on : Wednesday, June 10, 2020 - 2:06:49 PM

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Identifiers

Collections

Citation

Export

Metrics

216

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Identifiers

Collections

Citation

Export

Share

Metrics

216